Zoetis (ZTS) Q4 2024 Earnings Call Transcript

Zoetis reported FY2024 revenue of $9.3B (8% reported, 11% operational) and adjusted net income of $2.7B (10% reported, 15% operational); key drivers included Simparica ($1.4B, +28% op), OA pain mAbs (Librela/Solensia $581M, +80% op) and dermatology ($1.6B, +17% op). Q4 revenue was $2.3B (+5% reported, +6% operational) with adj. net income $632M (+11% reported); gross margin improved to 70.7% (up 50bps) despite a ~40bps FX headwind. Management returned >$2.6B to shareholders in 2024 (record $1.9B buybacks, $786M dividends) and authorized a new $6B multi-year repurchase program; 2025 guidance: revenue $9.225–9.375B (6–8% organic operational growth), adjusted net income $2.7–2.75B, adjusted EPS $6.00–6.10, with FX headwinds ~-$250M revenue/-$50M adj. net income and guidance excluding unapproved products (e.g., long-acting OA pain).

Analysis

The company has moved its portfolio toward higher-margin, science-led therapeutics while exiting low-value, volume-driven feed additives — that mix shift is an underappreciated margin lever. Expect incremental gross-margin expansion over the next 12–24 months driven not just by price but by a structural tilt to biologics and long-acting formats that carry both higher ASPs and recurring clinic-based revenue.

A multi-year buyback program plus accelerating alternative-channel auto-ship adoption creates a potent EPS tailwind that management has not baked fully into near-term guidance; this is classic convexity for equity holders because repurchases amplify upside from any organic beat while downside is capped by high cash generation. Conversely, currency and foreign-tax pressures are real and act as a stealth tax on international unit growth — a stronger dollar can erase several points of reported growth without any change in underlying demand.

Commercial optionality is the dominant asymmetric upside: late-stage/regulatory readouts and approvals for long-acting or chronic-disease assets could expand TAMs materially and are not in base guidance. Near-term risks that could reverse momentum include (1) competitive launches that accelerate price/mix erosion in certain therapeutic classes, (2) safety/regulatory headlines around novel biologics that slow clinic adoption curves, and (3) supply timing variability in a few key injectables which would produce lumpy revenue cadence through the next 6–12 months.

Key Decisions for Investors

• Long ZTS stock (size 2–4% of equity sleeve), buy on mild weakness: initiate on a 3–7% pullback or immediately on conviction. Time horizon 12–18 months to capture margin mix shift + buyback amplification; target asymmetric return 25–40% vs downside limited to company-specific/regulatory risk. Ticker: ZTS.
• Long-dated call spread to express pipeline optionality with defined cost: buy ZTS Jan 2026 1/2 OTM call and sell higher strike (ratio 1:1) to fund premium. Entry now–3 months; this captures upside from approvals/long-acting launches while capping premium spend; downside limited to paid premium.
• Protective put spread for near-term event risk (competition, FX): buy a 3–6 month ZTS put and sell a lower strike put to reduce cost (cost-limited hedge). Use if stock rallies into guidance season or if H2 competitor launches pick up; this hedges 6–12% downside scenarios at modest cost.
• Tactical pair (if constrained capital): long ZTS + short broad pet-consumer exposure is preferable; if limited to available tickers, prefer long ZTS over cyclical banks — ZTS is a defensive, cash-generative healthcare compounder with buybacks as optionality. Ticker: ZTS (long).